Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Balance Sheet: Assets
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Dividend Discount Model (DDM)
- Current Ratio since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Vertex Pharmaceuticals Inc. net fixed asset turnover ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023 not reaching Q2 2023 level. |
Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Vertex Pharmaceuticals Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Vertex Pharmaceuticals Inc. total asset turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Vertex Pharmaceuticals Inc. equity turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Net Fixed Asset Turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||
Property and equipment, net | ||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||
Net fixed asset turnover1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Moderna Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Net fixed asset turnover
= (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Vertex Pharmaceuticals Inc. net fixed asset turnover ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023 not reaching Q2 2023 level. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Vertex Pharmaceuticals Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||
Property and equipment, net | ||||||||||||||||||||||||||
Operating lease assets | ||||||||||||||||||||||||||
Property and equipment, net (including operating lease, right-of-use asset) | ||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||
Net fixed asset turnover (including operating lease, right-of-use asset)1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||||||||||||||||||||||
Moderna Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset)
= (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
÷ Property and equipment, net (including operating lease, right-of-use asset)
= ( + + + )
÷ =
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Vertex Pharmaceuticals Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Total Asset Turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||
Total asset turnover1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Moderna Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Total asset turnover
= (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Vertex Pharmaceuticals Inc. total asset turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Equity Turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||
Shareholders’ equity | ||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||
Equity turnover1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Equity Turnover, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||
Moderna Inc. | ||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Equity turnover
= (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
÷ Shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Vertex Pharmaceuticals Inc. equity turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |